Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Argye Elizabeth Hillis MD, MA Associate Editor

Marinos C. Dalakas MD, FAAN Advisory Board

Nina F. Schor MD, PhD Advisory Board

See All Experts

Published in Neurology and

Journal Scan / Research · December 21, 2024

Differences in Treatment Outcomes Between Patients With MS Receiving Ocrelizumab and Those Receiving Ofatumumab

Annals of Neurology

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Ahmed Obeidat MD, PhD

Annals of Neurology

Different Treatment Outcomes of Multiple Sclerosis Patients Receiving Ocrelizumab or Ofatumumab

Ann. Neurol 2024 Nov 25;[EPub Ahead of Print], SG Meuth, S Wolff, A Mück, A Willison, K Kleinschnitz, S Räuber, M Pawlitzki, FF Konen, T Skripuletz, M Grothe, T Ruck, HB Huttner, C Kleinschnitz, T Bopp, R Pul, BAC Cree, HP Hartung, K Möllenhoff, S Pfeuffer

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Multiple Sclerosis

Differences in Treatment Outcomes Between Patients With MS Receiving Ocrelizumab and Those Receiving Ofatumumab

Additional Info

Different Treatment Outcomes of Multiple Sclerosis Patients Receiving Ocrelizumab or Ofatumumab

Further Reading

Association of the Cervical Canal Area With Disability and Progression in People With MS

Directional Subthalamic Deep Brain Stimulation Better Improves Gait and Balance Disorders in Patients With Parkinson's Disease

Induction Cyclophosphamide With Maintenance Immunosuppression for High-Risk Myasthenia Gravis

Non-Invasive Continuous Oral Delivery of Solid Levodopa–Carbidopa for the Management of Parkinson's Disease

Low-Frequency Deep Brain Stimulation During Non-REM Sleep Modifies Memory Retention in Patients With Parkinson's Disease

Toward Personalized Dosing of B-Cell–Depleting Therapy

Safety and Efficacy of Intravenous Recombinant Human Prourokinase for Acute Ischaemic Stroke Within 4.5 Hours After Stroke Onset

Hypogammaglobulinemia and Severe Infections in Patients With MS on Anti-CD20 Agents

Risk of Hypertension in Patients With MS Treated With Teriflunomide vs Dimethyl Fumarate

Addition of Cilostazol to Antiplatelet Therapy for In-Stent Restenosis After Carotid Artery Stenting

2024 Top Story in Neurology: Management and Diagnosis of Multiple Sclerosis

Recently Updated